Impact of Dapagliflozin (Sodium-glucose Transport Protein 2 Inhibitor) on Liver Steatosis and Fibrosis in Subjects with Type 2 Diabetes Mellitus and Metabolic Dysfunction-associated Steatotic Liver Disease.
A diabetes drug reduced liver fat and scarring in patients with both diabetes and fatty liver disease, suggesting heart and liver protection together.
Dapagliflozin treatment in T2DM+MASLD patients was associated with significant reductions in liver steatosis and fibrosis markers, supporting SGLT2 inhibitor hepatoprotective benefits in cardiometabolic comorbidity. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- observational_study
- Category
- cardiovascular_metabolic
- Maturity
- Validated
- Journal
- Annals of African Medicine
Why it surfaced
SGLT2 inhibitor hepatoprotective effects in T2DM+MASLD; relevant to cardiometabolic precision medicine and expanding SGLT2 inhibitor benefit profiling.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.